Replies to post #68410 on Biotech Values

[DewDiligence]

>However, Onyx only gets a 7% royalty from Japan.<

Even though Bayer exclusively funded the clinical development in Japan, a 7% royalty rate seems unduly low. I suppose this is the price for ONXX’s having inked favorable economic terms elsewhere in the world.